Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis

• DOI: 10.1007/s00011-014-0761-1
• Publication Date: 2014-08-13T12:40:01Z
• Authors: Sumei Sha; Bin Xu; Xiangyun Kong; Ni Wei; Jian Liu; Kaichun Wu
• Keywords: 0301 basic medicine; Colon; Tumor Necrosis Factor-alpha; Probiotics; Anti-Inflammatory Agents; Colitis; Interleukin-10; 3. Good health; Rats, Sprague-Dawley; Disease Models, Animal; 03 medical and health sciences; Trinitrobenzenesulfonic Acid; Ileum; Escherichia coli; Zonula Occludens-1 Protein; Animals; Female; Intestinal Mucosa; Peroxidase

To analyze the in vivo effect of Escherichia coli Nissle 1917 (EcN) with different courses and different doses to Sprague-Dawley rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis.The probiotic was orally administered with different courses of treatment (with or without pre-administration) and different doses (10(7)-10(9) CFU/day) to Sprague-Dawley rats with TNBS-induced colitis. Therapeutic effects, levels of cytokine in serum, mRNA and protein expression were analyzed.Oral EcN administration after TNBS-induced improved colitis dose dependently. In parallel, a reduction of disease activity index and colonic MPO activity together with a decreased level of TNF-α and a trend of increased IL-10 expression was detected. Pre-administration of 10(7)CFU/day EcN to TNBS-treated rats resulted in a significant protection against inflammatory response and colons isolated from these rats exhibited a more pronounced expression of ZO-1 than the other groups. In the group of pre-administration of 10(9)CFU/day, the condition was not improved but deteriorated.This study convincingly demonstrates that pre-administration of probiotic EcN with low dose is able to protect colitis of rats and mediate up-regulation of ZO-1 expression, but long-term of high-dose EcN may do harm to colitis.